Ondine Biopharma Corporation

This company is devoting to the development of non-antibiotic anti-infective therapies for a wide spectrum of bacterial, viral and fungal infections.

Their main platform technology is called Photodisinfection that is a non-antibiotic approach to topical disinfection that destroys a broad range of microbes and their virulence factors. The photosensitizing solution can be modified for use in various indications to increase efficacy and ease of use.

Ondine Biomedical’s lead product is the MRSAid™ nasal decolonization system which is used in order to decolonize the nares of methicillin-resistant Staphylococcus aureus (MRSA).

Their next technology platforms are Periowave - treatment of gum disease and Exelume that eliminates bacterial biofilms on the inner surface of endotracheal tubes.